CBIZ CPAs

MRF Melanoma Research Foundation

MELANOMA RESEARCH FOUNDATION

FINANCIAL STATEMENTS

For the Year Ended March 31, 2026
(With Summarized Financial Information for the Year Ended March 31, 2025)

MELANOMA RESEARCH FOUNDATION

Table of Contents

Page

Independent Auditors' Report 1-2

Financial Statements

Statements of Financial Position 3
Statements of Activities 4
Statements of Functional Expenses 5
Statements of Cash Flows 6

Notes to Financial Statements 7-19

CBIZ CPAs P.C.

1899 L Street, NW
Suite 850
Washington, DC 20036

P: 202.227.4000

Independent Auditors' Report

The Board of Directors of the
Melanoma Research Foundation

Opinion

We have audited the financial statements of the Melanoma Research Foundation (the "Organization"), which comprise the statement of financial position as of March 31, 2026, and the related statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the financial statements (collectively referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Organization as of March 31, 2026, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America ("GAAS"). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Organization and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern for one year after the date that the financial statements are available to be issued.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- exercise professional judgment and maintain professional skepticism throughout the audit.
- identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control. Accordingly, no such opinion is expressed.
- evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Other Matter

Report on Summarized Comparative Information

We have previously audited Melanoma Research Foundation's 2025 financial statements, and we expressed an unmodified audit opinion on those audited financial statements in our report dated October 9, 2025. In our opinion, the summarized comparative information presented herein as of and for the year ended March 31, 2025, is consistent, in all material respects, with the audited financial statements from which it has been derived.

CBIZ CPAs P.C.

Washington, D.C.
October 19, 2026

MELANOMA RESEARCH FOUNDATION

STATEMENTS OF FINANCIAL POSITION

March 31, 2026
(With Summarized Financial Information for the Year Ended March 31, 2025)

	2026	2025
Assets		
Cash and cash equivalents	$ 152,811	$ 498,466
Investments	6,050,290	3,736,699
Pledges and grants receivable	3,036,876	1,587,212
Prepaid expenses and deposits	78,338	284,107
Property and equipment, net	135,614	212,708
Assets held for sale	--	1,045,538
Right of use asset - operating	745,665	918,309
Total Assets	$ 10,199,594	$ 8,283,039
Liabilities and Net Assets		
Liabilities		
Accounts payable and accrued expenses	$ 457,331	$ 508,046
Grants payable	1,757,796	1,635,193
Operating lease liabilities	990,984	1,200,876
Total Liabilities	3,206,111	3,344,115
Net Assets		
Without donor restrictions	2,475,249	1,185,628
With donor restrictions	4,518,234	3,753,296
Total Net Assets	6,993,483	4,938,924
Total Liabilities and Net Assets	$ 10,199,594	$ 8,283,039

The accompanying notes are an integral part of these financial statements.

MELANOMA RESEARCH FOUNDATION

STATEMENTS OF ACTIVITIES

For the Year Ended March 31, 2026
(With Summarized Financial Information for the Year Ended March 31, 2025)

	Without Donor Restrictions	With Donor Restrictions	2026	2025
Revenue and Support				
Grants and contributions	$ 2,901,742	$ 2,354,913	$ 5,256,655	$ 5,319,459
Special events	--	2,764,062	2,764,062	2,617,729
In-kind contributions	469,016	672,633	1,141,649	958,145
Registration fees	280,944	--	280,944	255,303
Other income	102,983	--	102,983	18,288
Gain on sale of property	864,694	--	864,694	--
Investment income, net	166,815	140,872	307,687	52,646
Net assets released from restrictions:				
Satisfaction of program restrictions	2,293,937	(2,293,937)	--	--
Satisfaction of time restrictions	2,873,605	(2,873,605)	--	--
Total Revenue and Support	9,953,736	764,938	10,718,674	9,221,570
Expenses				
Program Services				
Research	3,430,937	--	3,430,937	3,185,131
Education	1,853,536	--	1,853,536	2,078,641
Advocacy	1,239,884	--	1,239,884	1,291,482
Total Program Services	6,524,357	--	6,524,357	6,555,254
Supporting Services				
General and administrative	358,316	--	358,316	1,092,273
Fundraising – other	1,695,692	--	1,695,692	1,006,020
Fundraising – cost of direct benefit to donors	85,750	--	85,750	78,000
Total Supporting Services	2,139,758	--	2,139,758	2,176,293
Total Expenses	8,664,115	--	8,664,115	8,731,547
Change in Net Assets	1,289,621	764,938	2,054,559	490,023
Net Assets, Beginning of Year	1,185,628	3,753,296	4,938,924	4,448,901
Net Assets, End of Year	$ 2,475,249	$ 4,518,234	$ 6,993,483	$ 4,938,924

The accompanying notes are an integral part of these financial statements.

MELANOMA RESEARCH FOUNDATION

STATEMENTS OF FUNCTIONAL EXPENSES

For the Year Ended March 31, 2026
(With Summarized Financial Information for the Year Ended March 31, 2025)

	Program Services				Supporting Services			
	Research	Education	Advocacy	Total Program Services	General and Administrative	Fundraising	2026 Total	2025 Total
Personnel	$ 719,719	$ 765,564	$ 478,057	$ 1,963,340	$ 141,464	$ 370,658	$ 2,475,462	$ 2,480,836
Professional services	322,485	493,038	375,917	1,191,440	116,125	493,892	1,801,457	2,153,276
Grants	1,874,838	--	--	1,874,838	--	--	1,874,838	1,598,184
Conferences	189,578	225,419	164,617	579,614	1,082	519,444	1,100,140	999,262
Facilities	150,405	122,825	78,269	351,499	59,714	177,989	589,202	646,843
Other	87,611	102,038	51,235	240,884	33,065	132,607	406,556	367,864
Travel	54,914	63,213	64,686	182,813	3,370	42,424	228,607	279,927
Operations	31,387	81,439	27,103	139,929	3,496	44,428	187,853	205,355
Total Expenses	$ 3,430,937	$ 1,853,536	$ 1,239,884	$ 6,524,357	$ 358,316	$ 1,781,442	$ 8,664,115	$ 8,731,547

The accompanying notes are an integral part of these financial statements.

MELANOMA RESEARCH FOUNDATION

STATEMENTS OF CASH FLOWS

For the Year Ended March 31, 2026
(With Summarized Financial Information for the Year Ended March 31, 2025)

	2026	2025
Cash Flows From Operating Activities		
Change in net assets	$ 2,054,559	$ 490,023
Adjustments to reconcile change in net assets to net cash (used in) provided by operating activities:		
Depreciation and amortization	77,094	56,475
Net realized and unrealized investment (gains) losses	(216,482)	1,554
Amortization of operating right-of-use asset	172,644	168,316
Contributions restricted for long-term purposes	(150,000)	(1,056,358)
Transfer of assets held for sale from pledge receivable	--	(1,045,538)
Gain on sale of donated property	(864,694)	--
Changes in assets and liabilities:		
Pledges and grants receivable	(1,449,664)	2,313,200
Prepaid expenses and deposits	205,769	(14,506)
Accounts payable and accrued expenses	(50,715)	91,449
Grants payable	122,603	627,252
Operating lease liability	(209,892)	(196,557)
Net Cash (Used in) Provided by Operating Activities	(308,778)	1,435,310
Cash Flows From Investing Activities		
Purchases of investments	(2,320,383)	(2,069,560)
Sales of investments	277,033	98,104
Sales of donated property	1,910,232	--
Purchase of property and equipment	--	(54,621)
Net Cash Used in Investing Activities	(133,118)	(2,026,077)
Cash Flows From Financing Activities		
Contributions restricted for long-term purposes	150,000	1,056,358
Net Cash Provided by Financing Activities	150,000	1,056,358
Net (Decrease) Increase in Cash and Cash Equivalents	(291,896)	465,591
Cash and Cash Equivalents, Beginning of Year	856,272	390,681
Cash and Cash Equivalents, End of Year	$ 564,376	$ 856,272
Cash and Cash Equivalents, End of Year		
Cash and cash equivalents	$ 152,811	$ 498,466
Cash and cash equivalents held within investments	411,565	357,806
Total Cash and Cash Equivalents	$ 564,376	$ 856,272

The accompanying notes are an integral part of these financial statements.

NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

ORGANIZATION

The Melanoma Research Foundation (the "Foundation") was incorporated on October 7, 1996, under the laws of Texas. Its mission is to eradicate melanoma by accelerating medical research while educating to and advocating for the melanoma community. The activities of the Foundation are funded primarily from grants and contributions from individuals and foundations.

CASH EQUIVALENTS

The Foundation considers all money market accounts to be cash equivalents.

PLEDGES AND GRANTS RECEIVABLE

Pledges and grants receivable represent unconditional contributions from foundations and individuals. Unconditional pledges and grants receivable are recorded at the present value of their estimated future cash flows. Pledges and grants receivable are reviewed for collectibility, and a provision for doubtful pledges and grants receivable is recorded based on management's judgment and analysis of the creditworthiness of the donors, past collection experience, and other relevant factors.

PROPERTY AND EQUIPMENT AND RELATED DEPRECIATION AND AMORTIZATION

Computer and software, and eligible website costs with an acquisition value of $5,000 or greater are stated at cost and are depreciated/amortized using the straight-line method over the assets' estimated service lives of three to seven years. Leasehold improvements are amortized over the shorter of their useful life or the remaining life of the lease. Expenditures for major additions, renewals and betterments are capitalized. Expenditures for property and equipment with an acquisition value of less than $5,000, minor repairs and maintenance costs are expensed when incurred. Upon the retirement or disposal of assets, the cost and accumulated depreciation and amortization are eliminated from the accounts and the resulting gain or loss is included in revenue or expenses.

INVESTMENTS

The Foundation invests in a professionally managed portfolio that contains marketable equity securities and mutual funds. Investments are reported in the accompanying statement of financial position at fair value. Fair value is the price that would be received to sell an asset, or paid to transfer a liability through an orderly transaction between market participants at the measurement date. Purchases and sales are reflected on a trade date basis. Interest, dividends and realized gains or losses are recorded when earned. Changes in the fair value of the portfolio are recorded as unrealized gains or losses. Donated investments are recorded as contributions based on their fair value at the date of donation.

NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

FAIR VALUE MEASUREMENT

In accordance with accounting standards for fair value measurement for those assets and liabilities that are measured at fair value on a recurring basis, the Foundation has categorized its applicable financial instruments into a three-level fair value hierarchy. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest-level input that is significant to the fair value measurement of the instrument.

Applicable financial assets and liabilities are categorized based on the inputs to the valuation techniques as follows:

Level 1 – Financial assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market that the Foundation has the ability to access.

Level 2 – Financial assets and liabilities whose values are based on quoted prices in markets that are not active or model inputs that are observable either directly or indirectly for substantially the full term of the asset or liability.

Level 3 – Financial assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management's assumptions about the assumptions a market participant would use in pricing the asset or liability.

As of March 31, 2026, the Foundation's investments, as described in Note 3 of these financial statements, were measured at fair value on a recurring basis.

CLASSIFICATION OF NET ASSETS

The Foundation's net assets are reported as follows:

- Net assets without donor restrictions represent the portion of expendable funds that are available for any purpose in performing the primary objectives of the Foundation at the discretion of the Foundation's management and the Board of Directors (the "Board"). The Board designated endowment funds are net assets without donor restrictions designated by the Board of Directors. The Board designated endowment funds result primarily from bequests that are received that are designated for use in operations by the Board of Directors.

- Net assets with donor restrictions represent amounts that are specifically restricted by donors or grantors for various programs, specific future time periods, or the endowment funds of the Foundation, which are required to be held in perpetuity.

NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

REVENUE RECOGNITION

The Foundation recognizes revenue and support from grants, contributions and bequests when they become unconditional. Unconditional grants and contributions are recorded as net assets with donor restriction if they are received with donor stipulations that limit the use of the donated asset. When a stipulated time restriction ends or purpose restriction is met, net assets with donor restrictions are reclassified to net assets without donor restriction and reported in the accompanying statement of activities as net assets released from restrictions. Conditional promises to give – that is, those with a measurable performance or other barrier and a right of return, are not recognized until the conditions on which they depend have been met. As of March 31, 2026, there were no conditional contributions with amounts yet to be recognized.

Special events revenue consists of unconditional contributions related to gala events and walks. Contributions are recorded as with or without donor restrictions based on whether they are restricted for a particular purpose or to a specific time as noted above.

IN-KIND CONTRIBUTIONS

The Foundation's programs are furthered through in-kind contributions of services by various individuals and organizations. In-kind contributions also include donated advertising and marketing services, which were used in program and fundraising activities. In-kind contributions are recorded at fair value as of the date of donation and are included in in-kind contribution revenue in the accompanying statement of activities.

The Foundation also utilizes volunteers who contribute their time and perform a variety of tasks to assist with the Foundation's program services. No amounts have been recorded in the accompanying statement of activities related to these volunteer services because they do not meet the criteria for recognition as donated services under accounting standards.

GRANT EXPENSE RECOGNITION

The Foundation provides multiyear grants to universities for research purposes. Grants are expensed in the year in which an unconditional commitment is made. Unconditional grant awards for which payments have not been made are included in grants payable in the accompanying statement of financial position. Conditional grants are not included as expenses until such time as the conditions are met. As of March 31, 2026, there were no conditional grant awards.

NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

FUNCTIONAL ALLOCATION OF EXPENSES

The costs of providing the various programs and other activities have been summarized on a functional basis in the accompanying statement of functional expenses. Expenses directly attributed to a specific functional area of the Foundation are reported as expenses of those functional areas, while shared costs that benefit multiple functional areas have been allocated among the various functional areas based on estimates determined by management to be equitable. Occupancy and depreciation expenses are allocated by the square footage used by the related department, and costs that are part of the direct mail and telemarketing campaigns are allocated based on the line counts of the direct mail and telemarketing pieces. All other shared costs are allocated based on a time study which is done annually.

ESTIMATES

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

NOTE 2 – PLEDGES AND GRANTS RECEIVABLE

Pledges and grants receivable include unconditional promises to give from foundations, corporations and individual donors, which were due as follows as of March 31, 2026:

Less than one year	$ 2,837,209
One to five years	149,667
More than five years	50,000
Pledges and Grants Receivable	$ 3,036,876

As of March 31, 2026, all pledges and grants were considered by management to be fully collectible. The present value factor of grants receivable due in one to five years and more than five years was not considered significant to the Foundation's financial statements and, accordingly, not recognized in these financial statements.

NOTE 3 – INVESTMENTS AND FAIR VALUE MEASUREMENT

The following table summarizes the Foundation's investments measured at fair value on a recurring basis as of March 31, 2026, aggregated by the fair value hierarchy level with which those measurements were made:

NOTE 3 – INVESTMENTS AND FAIR VALUE MEASUREMENT (CONTINUED)

	Total Fair Value	Quoted Prices in Active Markets for Identical Assets/ Liabilities (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Assets:				
Equities	$ 3,629,419	$ 3,629,419	$ --	$ --
Mutual funds	2,009,306	2,009,306	--	--
Total Investments Classified in the Fair Value Hierarchy	5,638,725	$ 5,638,725	$ --	$ --
Cash and cash equivalents	411,565			
Total Investments	$ 6,050,290			

The Foundation used the following methods and significant assumptions to estimate fair value for assets measured at fair value:

Equities and mutual funds – Measured using quoted market prices for identical assets in active markets.

NOTE 4 – PROPERTY AND EQUIPMENT

The Foundation held the following property and equipment as of March 31, 2026:

Computers, software and website	$ 518,702
Leasehold improvements	170,608
Total Property and Equipment	689,310
Less: Accumulated Depreciation and Amortization	(553,696)
Property and Equipment, Net	$ 135,614

For the year ended March 31, 2026, depreciation and amortization expense was $77,094. This amount is included in other expenses in the accompanying statement of functional expenses.

NOTE 5 – GRANTS PAYABLE

The Foundation awards unconditional grants that can be payable over several years. Expected payments on grants payable consisted of the following as of March 31, 2026:

Less than one year	$ 1,552,064
One to five years	205,732
Total Grants Payable	$ 1,757,796

The present value factor of grants payable due in one to five years was not considered significant to the Foundation's financial statements and, accordingly, not recognized in these financial statements.

NOTE 6 – LINE OF CREDIT

The Foundation has a line of credit secured by their investments with a bank for $500,000. Borrowings on the loan accrue interest, which was 7.27% at March 31, 2026. The loan is held until a termination agreement is made by the Foundation or the bank. As of March 31, 2026, the Foundation had no borrowings on the line of credit.

NOTE 7 – NET ASSETS WITH DONOR RESTRICTIONS

As of March 31, 2026, net assets with donor restrictions were restricted for the following purposes or period:

Subject to expenditure for specified purpose:	
Education	$ 354,270
Unspent endowment earnings for the Legacy of Progress	328,090
Research grants	282,500
Advocacy	175,500
Ocular melanoma program	135,794
Mucosal melanoma program	26,389
Pediatric melanoma program	25,704
Acral melanoma program	20,075
Total Subject to Expenditure for Specified Purpose	1,348,322
Subject to occurrence of specified events and time:	
Galas – time-restricted for fiscal year 2027	320,528
Miles for Melanoma – time-restricted for fiscal year 2027	428,186
Time restricted	19,750
Perpetual in nature, endowment fund for the Legacy of Progress	2,401,448
Total Subject to Occurrence of Specified Events and Time	3,169,912
Total Net Assets With Donor Restrictions	$ 4,518,234

NOTE 8 – ENDOWMENT NET ASSETS

The Legacy of Progress Endowment Fund is an established fund of cash, securities, or other assets invested in perpetuity to provide long-term funding for the Foundation's peer-reviewed research grant program. The fund is professionally managed by a financial institution and overseen by the Foundation's Investment Committee employing conservative and professional expertise to foster the long-term growth of the fund.

Interpretation of Relevant Law

The Board of Directors of the Foundation has interpreted the enacted version of the District of Columbia Uniform Prudent Management of Institutional Funds Act ("UPMIFA") as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds, absent explicit donor stipulations to the contrary. As a result of this interpretation, the Foundation classifies as net assets with donor restrictions the historical value of gifts donated to the permanent endowment and the related appreciation. Applicable accumulated amounts are

NOTE 8 – ENDOWMENT NET ASSETS (CONTINUED)

Interpretation of Relevant Law (Continued)
appropriated for expenditure by the Foundation in a manner consistent with the standard of prudence prescribed by UPMIFA. In accordance with UPMIFA, the Foundation considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds:

- The duration and preservation of the fund.
- The purposes of the Foundation and the donor-restricted endowment fund.
- General economic conditions.
- The possible effects of inflation and deflation.
- The expected total return from income and the appreciation of investments.
- Other resources of the Foundation.
- The investment policies of the Foundation.

Return Objectives and Risk Parameters
The mission of the Foundation's long-term investment pool is to provide a common investment vehicle that will generate a stable and continuously growing income stream for the Foundation's endowment, for which the Foundation is both the trustee and the beneficiary. The overall goal of the investment pool is to preserve the purchasing power of the future stream of endowment payout for those funds and activities supported by the endowments and, to the extent this is achieved, to cause the principal to grow in value over time. Other goals include:

- To maximize return within reasonable and prudent levels of risk.
- To maximize the value of the endowment while maintaining liquidity needed to support spending in prolonged down markets.

Strategies Employed for Achieving Objectives
Extensive diversification is sought at all times. Experience has shown that financial markets and inflation rates are cyclical and, therefore, control of volatility will be achieved through diversification of asset classes and selection of managers of diverse investment styles. The Board of Directors examines the correlation of historic returns among each asset class and manager. Investment managers are appointed following a systematic search for those with demonstrated quality in the style desired. Managers are given discretion to manage funds entrusted in accordance with the style for which they are employed, provided they comply with the restrictions and limitations that may be determined by the Foundation from time to time.

Spending Policy
The Foundation will appropriate for expenditure no more than 5% of the total market value of endowment principal in any single fiscal year in order to balance the effects of inflation as well as continue to maintain endowment principal.

NOTE 8 – ENDOWMENT NET ASSETS (CONTINUED)

Funds with Deficiencies

From time to time, the fair value of assets associated with individual endowment funds may fall below the fair value of the original gifts. Deficiencies of this nature are reported as part of net assets with donor restrictions. The Foundation's policy is not to appropriate from deficient funds in accordance with its spending policy. As of March 31, 2026, deficiencies of this nature do not exist in the endowment funds.

As of March 31, 2026, the Foundation's endowment had the following net asset composition:

	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted endowment funds:			
Historical gift value	$ --	$ 2,401,448	$ 2,401,448
Appreciation	--	328,090	328,090
Board-designated endowment fund	4,178,400	--	4,178,400
Endowment Net Assets, End of Year	$ 4,178,400	$ 2,729,538	$ 6,907,938

The endowment activity was as follows for the year ended March 31, 2026:

	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets, beginning of year	$ 2,801,862	$ 2,451,693	$ 5,253,555
Net investment income	161,844	140,872	302,716
Contributions/Additions	1,464,694	150,000	1,614,694
Appropriation of endowment assets for expenditure	(250,000)	(13,027)	(263,027)
Endowment Net Assets, End of Year	$ 4,178,400	$ 2,729,538	$ 6,907,938

NOTE 9 – IN-KIND CONTRIBUTIONS

Donated goods and services are recognized if the services received create or enhance long-lived assets or require specialized skills, that are provided by individuals possessing those skills and would typically need to be purchased if not donated. For the year ended March 31, 2026, in-kind contributions received by the Foundation consisted of the following:

Professional services – branding, legal, marketing, and advocacy	$ 1,133,754
Advertising	7,895
Total In-Kind Contributions	$ 1,141,649

The donated professional services are recorded at the estimated fair value based on market rates for similar services in the United States. The donated advertising is recorded at the estimated fair value based on current market rates for similar advertising. These items are reported as in-kind contributions in the statement of activities. There were no donor-imposed restrictions associated with the donated goods and services.

For the year ended March 31, 2026, in-kind expenses were recognized in the following functional areas:

Advocacy	$ 311,553
Education	374,693
Research	140,702
Management and general	34,475
Fundraising	280,226
Total In-Kind Expenses	$ 1,141,649

In prior year, the Foundation received donated real property valued at $1,045,538, which was recorded as contribution revenue upon receipt. The property was sold during the year ended March 31, 2026 for $1,910,232, resulting in a realized gain of $864,694, which is included in the accompanying statement of activities.

NOTE 10 – COMMITMENTS, CONTINGENCIES AND RISKS

CONCENTRATION OF CREDIT RISK

Accounts per depositor per institution are insured by the Federal Deposit Insurance Corporation ("FDIC") up to $250,000. There were no amounts held in excess of FDIC insurance coverage at March 31, 2026. The Foundation monitors the creditworthiness of these financial institutions and has not experienced any losses on its cash.

NOTE 10 – COMMITMENTS, CONTINGENCIES AND RISKS (CONTINUED)

INVESTMENT RISK

The Foundation also invests in various investment securities that are exposed to various risks, including market, interest rate and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of the investment securities will occur in the near term and that such changes could materially affect the amounts reports in the financial statements.

NOTE 11 – OPERATING LEASE

In April 2019, the Foundation entered into a noncancelable agreement for office space at a different office building location. The lease term commenced on August 1, 2019 and expires June 30, 2030. The first year base rent was $188,820 per year, payable in equal monthly installments of $15,735. The lease contains an escalation clause for increase in the annual base rent of 4% and provisions for 50% abated rent for the first 16 months of the lease term. The Foundation is also responsible for its proportionate share of building operating expenses and taxes.

Operating lease cost totaled $200,027 for the year ended March 31, 2026 and are included in facilities in the accompanying statement of functional expenses. Cash paid for operating leases for the year ended March 31, 2026 totaled $237,339. The Foundation used a risk-free rate of 2.5% to calculate the present value discount. There were no noncash investing and financing transactions related to leasing.

As of March 31, 2026, future minimum lease payments under the lease were as follows:

For the Year Ending March 31,	Amount
2027	$ 245,289
2028	255,100
2029	265,304
2030	275,916
Total	1,041,609
Less: Present value discount	(50,625)
Operating Lease Liability	$ 990,984

NOTE 12 – LIQUIDITY AND AVAILABILITY OF FUNDS

The Foundation regularly monitors liquidity required to meet its annual operating needs and other contractual commitments, while also striving to preserve the principal and return on the investment of its funds. The Foundation's financial assets available within one year of the statement of financial position date for general expenditures at March 31, 2026, were as follows:

Cash and cash equivalents	$ 152,811
Investments	6,050,290
Pledges and grants receivable, net	3,036,876
Total Financial Assets Available Within One Year	9,239,977
Less amounts not available to be used within one year:	
Amounts unavailable to management without Board approval:	(4,178,400)
Net assets with donor restrictions	(4,518,234)
Net assets expected to be released from time restrictions in a year	748,714
Total Financial Assets Available to Meet General Expenditures Within One Year	$ 1,292,057

The Foundation has various sources of liquidity at its disposal, including cash and cash equivalents, which are available for general expenditures, liabilities and other obligations as they come due. Management is focused on sustaining the financial liquidity of the Foundation throughout the year. This is done through monitoring and reviewing the Foundation's cash flow needs on a weekly basis. As a result, management is aware of the cyclical nature of the Foundation's cash flow related to the Foundation's various funding sources and is therefore able to ensure that there is cash available to meet current liquidity needs. Additionally, the Foundation has a board-designated endowment fund that could be liquidated and made available for current operations with Board approval, if necessary.

NOTE 13 – PENSION PLAN

The Foundation has a Savings Incentive Match Plan for Employees Individual Retirement Account ("SIMPLE IRA") plan. Employees are allowed to participate in the plan following a 90-day probationary period after hire. The Foundation contributes up to a 3% match of the employee's base salary. Employees are immediately fully vested in any employer match. Total pension expense for the year ended March 31, 2026, was $50,145.

NOTE 14 – INCOME TAXES

The Foundation is exempt from the payment of taxes on income other than unrelated business income under Internal Revenue Code Section 501(c)(3) and has been classified as public charities. For the year ended March 31, 2026, no provision for income taxes was made, as the Foundation had no significant net unrelated business income.

The Foundation adopted the authoritative guidance relating to accounting for uncertainty in income taxes included in FASB ASC Topic 740, *Income Taxes*. These provisions provide consistent guidance for the accounting for uncertainty in income taxes recognized in an entity's financial statements and prescribe a threshold of "more likely than not" for recognition and derecognition of tax positions taken or expected to be taken in a tax return. The Foundation performed an evaluation of uncertainty in income taxes for the year ended March 31, 2026, and determined that there were no matters that would require recognition in the financial statements or that may have any effect on its tax-exempt status. As of March 31, 2026, the statute of limitations remained open with the U.S. federal jurisdiction or the various states and local jurisdictions in which the Foundation files tax returns; however, there are currently no audits for any tax periods pending or in progress. It is the Foundation's policy to recognize interest and/or penalties related to uncertainty in income taxes, if any, in income tax or interest expense. As of March 31, 2026, the Foundation had no accruals for interest and/or penalties.

NOTE 15 – SUBSEQUENT EVENTS

In preparing these financial statements, the Foundation has evaluated events and transactions for potential recognition or disclosure through October 19, 2026, the date the financial statements were available to be issued. There were no subsequent events identified that require recognition or disclosure in these financial statements.